Clinical Trial Update: Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating eftozanermin alfa in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma has been terminated, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Eftozanermin alfa

Snippet

Sponsor: AbbVie | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED